id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-E-0245-0007,FDA,FDA-2011-E-0245,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2012-12-27T05:00:00Z,2012,12,2012-12-27T05:00:00Z,,2024-03-13T11:31:53Z,,0,0,090000648119c8ce
FDA-2011-E-0245-0006,FDA,FDA-2011-E-0245,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2012-04-09T04:00:00Z,2012,4,2012-04-09T04:00:00Z,,2024-03-13T12:08:31Z,,0,0,0900006480feb77f
FDA-2011-E-0245-0005,FDA,FDA-2011-E-0245,Determination of Regulatory Review Periods for Patent Extension: TEFLARO,Notice,General Notice,2012-04-06T04:00:00Z,2012,4,2012-04-06T04:00:00Z,2012-05-06T03:59:59Z,2014-07-02T15:52:43Z,2012-08339,0,0,0900006480feaa9c
FDA-2011-E-0245-0004,FDA,FDA-2011-E-0245,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2012-03-12T04:00:00Z,2012,3,2012-03-12T04:00:00Z,,2024-03-13T17:57:53Z,,0,0,0900006480fd3b2b